Compare · LTGO vs NVO
LTGO vs NVO
Side-by-side comparison of Latigo Biotherapeutics Inc. (LTGO) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LTGO and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $180.22B, about 197.5x LTGO ($912.3M).
- NVO has been more active in the news (9 items in the past 4 weeks vs 7 for LTGO).
- NVO has more recent analyst coverage (25 ratings vs 0 for LTGO).
- Company
- Latigo Biotherapeutics Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $912.3M
- $180.22B
- 1M return
- -
- +5.96%
- 1Y return
- -
- -14.37%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2026
- News (4w)
- 7
- 9
- Recent ratings
- 0
- 25
Latigo Biotherapeutics Inc.
Latigo Biotherapeutics is a private clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction, with the goal to provide effective, rapid-acting pain relief. Latigo is supported by leading investors, including Westlake Village BioPartners, Foresite Capital, 5AM Ventures, and Blue Owl Capital. Latigo's lead program is LTG-001, an oral, selective Nav1.8 inhibitor in development to treat acute pain.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest LTGO
- SEC Form SCHEDULE 13G filed by Latigo Biotherapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Latigo Biotherapeutics Inc.
- SEC Form 10-Q filed by Latigo Biotherapeutics Inc.
- Latigo Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits
- Latigo Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
- Latigo Biotherapeutics Announces CEO Transition to Support the Company’s Next Phase of Growth
- Latigo Biotherapeutics to Participate in Upcoming Investor Conferences in November
Latest NVO
- Novo launches the new Novocare®: Free support program connects people with Wegovy® in addition to home delivery, everyday support, wellness partners and rewards
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S